Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells.

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Cell

• Publication date

  1989-07-28

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/0092-8674(89)90844-1PMID 2568889
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA.

  2005cited by this paper
• T cell-recognized antigenic peptides derived from the cellular genome are not protein degradation products but can be generated directly by transcription and translation of short subgenic regions. A hypothesis

  2004cited by this paper
• A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes

  1989cited by this paper
• Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection.

  1989cited by this paper
• T-cell receptor Vβ use predicts reactivity and tolerance to Mlsa- encoded antigens

  1988cited by this paper
• A sequence pattern common to T cell epitopes.

  1988cited by this paper
• Synthetic peptides as antigens and competitors in recognition by H-2- restricted cytolytic T cells specific for HLA

  1988cited by this paper
• Antigenic heterogeneity of a human melanoma tumor detected by autologous CTL clones

  1988cited by this paper
• Molecular basis for cytolytic T-lymphocyte recognition of the murine cytomegalovirus immediate-early protein pp89

  1988cited by this paper
• Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation.

  1988cited by this paper
• Immunogenic (tum−) variants obtained by mutagenesis of mouse mastocytoma P815

  1987cited by this paper
• An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs.

  1987cited by this paper
• T cell tolerance by clonal elimination in the thymus.

  1987cited by this paper
• Is there a role for MHC class I antigens in the elimination of somatic mutants?

  1987cited by this paper
• Production of stable cytolytic T‐cell clones directed against autologous human melanoma

  1987cited by this paper
• 5'-structural analysis of genes encoding polymorphic antigens of chemically induced tumors.

  1987cited by this paper
• Host immune response to cytomegalovirus: products of transfected viral immediate-early genes are recognized by cloned cytolytic T lymphocytes

  1987cited by this paper
• The non-MHC transplantation antigens: neither weak nor minor.

  1986cited by this paper
• Cytotoxic T lymphocytes recognize influenza haemagglutinin that lacks a signal sequence

  1986cited by this paper
• The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides.

  1986cited by this paper
• Cloned long-term cytolytic T-lymphocyte line with specificity for an immediate-early membrane antigen of murine cytomegalovirus

  1986cited by this paper
• Cytotoxic T cells recognize fragments of the influenza nucleoprotein.

  1985cited by this paper
• Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors.

  1985cited by this paper
• Selection of highly transfectable variant from mouse mastocytoma P815

  1985cited by this paper
• Rapid and sensitive protein similarity searches.

  1985cited by this paper
• Unidirectional digestion with exonuclease III creates targeted breakpoints for DNA sequencing.

  1984cited by this paper
• Expression of H-2Dd and H-2Ld mouse major histocompatibility antigen genes in L cells after DNA-mediated gene transfer.

  1983cited by this paper
• Lambda replacement vectors carrying polylinker sequences.

  1983cited by this paper
• Antigenic tumor cell variants obtained with mutagens.

  1983cited by this paper
• Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VI. Occasional escape from host rejection due to antigen‐loss secondary variants

  1983cited by this paper
• Mutagen treatment as a means for selecting immunogenic variants from otherwise poorly immunogenic malignant murine tumors.

  1983cited by this paper
• A simple and very efficient method for generating cDNA libraries.

  1983cited by this paper
• Double cos site vectors: simplified cosmid cloning.

  1983cited by this paper
• Patterns of amino acids near signal-sequence cleavage sites.

  1983cited by this paper
• Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression

  1983cited by this paper
• New versatile cloning and sequencing vectors based on bacteriophage M13.

  1983cited by this paper
• Mouse histocompatibility genes: structure and organisation of a Kd gene.

  1983cited by this paper
• Patterns of Amino Acids near Signal‐Sequence Cleavage Sites

  1983cited by this paper
• The construction of cosmid libraries which can be used to transform eukaryotic cells.

  1982cited by this paper
• Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant‐specific antigens by selection of antigen‐loss variants with cytolytic T cell clones

  1982cited by this paper
• Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. V. H‐2 associativity of variant‐specific antigens

  1982cited by this paper
• Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response

  1982cited by this paper
• Immunologic mechanisms in UV radiation carcinogenesis.

  1981cited by this paper
• In vitro generation of a highly immunogenic subline of L1210 leukemia following exposure to 5-(3,3'-dimethyl-1-triazeno)imidazole-4-carboxamide.

  1981cited by this paper
• Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis

  1980cited by this paper
• Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice

  1980cited by this paper
• Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line.

  1978cited by this paper
• Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line.

  1977cited by this paper
• Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host.

  1960cited by this paper
• Immunity to methylcholanthrene-induced sarcomas.

  1957cited by this paper

• Characterization of Tumor Antigens from Multi-omics Data: Computational Approaches and Resources

  2025cites this paper
• Engineered T cells for Colorectal Cancer.

  2024cites this paper
• Tumor immune microenvironment (TIME) to enhance antitumor immunity

  2023cites this paper
• Cancer Immunology and Immunotherapy: From Defining Basic Immunology to Leading the Fight Against Cancer

  2022cites this paper
• Cancer Immunology: Bench to Bedside Immunotherapy of Cancers

  2021cites this paper
• The foundations of immune checkpoint blockade and the ipilimumab approval decennial

  2021cites this paper
• Hepatobiliary Cancers and Immunology

  2020cites this paper
• Progress in Neoantigen Targeted Cancer Immunotherapies

  2020cites this paper
• Neo-Antigen mRNA Vaccines

  2020cites this paper
• Antigen processing by epidermal Langerhans cells correlates with the level of biosynthesis of MHC class II molecules and expression of invariant chain

  2020cites this paper
• Personalized Neo-Epitope Vaccines for Cancer Treatment.

  2020cites this paper
• Current Immunotherapeutic Strategies in Cancer

  2020cites this paper
• Organized immune cell interactions within tumors sustain a productive T cell response.

  2020cites this paper
• The Landscape of Tumor-Specific Antigens in Colorectal Cancer

  2020cites this paper
• Analytical Approach to Cancer Therapy by Inhibition of Blockade Regulation in the Context of Protein Vibration

  2020cites this paper
• Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors.

  2020cites this paper
• Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process

  2020cites this paper
• Tumor Antigens

  2019cites this paper
• A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control

  2019cites this paper
• Mutant Epitopes in Cancer

  2018cites this paper
• Somatic Mutations and Immunotherapy

  2018cites this paper
• Targeting neoantigens to augment antitumour immunity

  2017cites this paper
• CONUGATES FOR INDUCING TARGETED MMUNE RESPONSES AND METHODS OF MAKING AND USING SAME

  2017cites this paper
• Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes

  2017cites this paper
• T cell receptor repertoire usage in cancer as a surrogate marker for immune responses

  2017cites this paper
• CTLA-4, an Essential Immune-Checkpoint for T-Cell Activation.

  2017cites this paper
• I MHCCan Recognize Different Forms of Class

  2017cites this paper
• mRNA Cancer Vaccines.

  2016cites this paper
• CD8 T Lymphocytes in Antitumor Immunity

  2016cites this paper
• Finding neoepitopes in mouse models of personalized cancer immunotherapy

  2016cites this paper
• Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination

  2015cites this paper
• Human Tumor Antigens and Cancer Immunotherapy

  2015cites this paper
• Cancer vaccines

  2015cites this paper
• Apprêtement non conventionnel de peptides antigéniques : production d’antigènes tumoraux par épissage inverse dans le protéasome ou par des protéases distinctes du protéasome

  2015cites this paper
• History of Immunology Research

  2015cites this paper
• Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy

  2014cites this paper
• Bioinformatics for cancer immunotherapy target discovery

  2014cites this paper
• Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer

  2014cites this paper
• Tumor antigen discovery through translation of the cancer genome

  2014cites this paper
• Large T Antigen Transgenic Mice Choroid Plexus Tumors in Simian Virus 40 Immunodominance in the Control of Cytotoxic T-Lymphocyte Epitope

  2013cites this paper
• Tumor Antigens Revealed By Exome Sequencing Drive Editing of Tumor Immunogenicity

  2013cites this paper
• Vaccines against advanced melanoma.

  2013cites this paper
• [At the crossroads of cancer].

  2013cites this paper
• Molecular pathways in hepatocyte proliferation 1

  2013cites this paper
• Au carrefour du cancer

  2013cites this paper
• On the Source of Peptides for Major Histocompatibility Class I Antigen Presentation: A Dissertation

  2012cites this paper
• Melanoma Antigens Recognized by T Lymphocytes

  2012cites this paper
• Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes

  2011cites this paper
• Tumor-Specific Antigens and Immunologic Adjuvants in Cancer Immunotherapy

  2011cites this paper
• Targeting the tumor microenvironment with anti-neu/anti-CD40 conjugated nanoparticles for the induction of antitumor immune responses.

  2010cites this paper
• Her-2/neu Transgenic Mice for Evaluation of Immune and Antitumor Responses Against Self-Tumor Antigens in the Young and the Old

  2009cites this paper
• Targeting the Intratumoral Dendritic Cells by the Oncolytic Adenoviral Vaccine Expressing RANTES Elicits Potent Antitumor Immunity

  2009cites this paper
• Immune rejection of mouse tumors expressing mutated self.

  2009cites this paper
• Vaccines as Targeted Cancer Therapy

  2008cites this paper
• The 26S Proteasome

  2008cites this paper
• Rapid accumulation of adoptively transferred CD8+ T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors

  2008cites this paper
• Human Major Histocompatibility Complex (MHC) Class I Molecules with Disulfide Traps Secure Disease-related Antigenic Peptides and Exclude Competitor Peptides*

  2008cites this paper
• A study on anti-tumor immunity induced by gene-modified melanoma B16 cells.

  2008cites this paper
• A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

  2007cites this paper
• T cell function in the aged: Lessons learned from animal models

  2006cites this paper
• Use of baculovirus MHC/peptide display libraries to characterize T‐cell receptor ligands

  2006cites this paper
• Engineering and characterization of a stabilized alpha1/alpha2 module of the class I major histocompatibility complex product Ld.

  2006cites this paper
• Alkylguanine-DNA Alkyltransferase Attenuates Triazeneinduced Cytotoxicity and Tumor Cell Immunogenicity in Murine L 1210 Leukemia '

  2006cites this paper
• Engineering and Characterization of a Stabilized α1/α2 Module of the Class I Major Histocompatibility Complex Product Ld*

  2006cites this paper
• Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets for T Cell–Mediated Patient-Specific Immunotherapy

  2006cites this paper
• Génération et mécanismes d'action anti-tumorale d'effecteurs lymphocytaires T CD4+ dans les lymphomes B malins

  2005cites this paper
• Immunization with mutagen-treated (tum−) cells causes rejection of nonimmunogenic rat glioma isografts

  2005cites this paper
• Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors

  2005cites this paper
• Peptide vaccines against cancer.

  2005cites this paper
• Cancer Treatment and Research

  2005cites this paper
• Mapping of the genes encoding tum- transplantation antigens P91A, P35B, and P198

  2004cites this paper
• Immune recognition of self in immunity against cancer.

  2004cites this paper
• Efficient expression of tum− antigen P91A by transfected subgenic fragments

  2004cites this paper
• Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes

  2004cites this paper
• A new approach to the cloning of genes encoding T-cell epitopes

  2004cites this paper
• Locus-specific de novo methylation down-regulates MHC class I in S49 lymphomas

  2004cites this paper
• Variable spread of X inactivation affecting the expression of different epitopes of the Hya gene product in mouse B-cell clones

  2004cites this paper
• Mutations inside but not outside the peptide binding cleft of the H-2 Ld molecule affects CTL recognition and binding of the nucleoprotein peptide from the lymphocytic chroriomeningitis

  2004cites this paper
• Immune responses against spontaneous tumors in a murine model for pancreatic adenocarcinoma

  2004cites this paper
• EVIDENCE FOR THE EXISTENCE OF CANCER IMMUNOSURVEILLANCE

  2004cites this paper
• Sequence and expression pattern of the human MAGE2 gene

  2004cites this paper
• MHC ligands and peptide motifs: first listing

  2004cites this paper
• Tum—mutation P35B generates the MHC-binding site of a new antigenic peptide

  2004cites this paper
• Subunits of the regulatory complex of the 26S protease

  2004cites this paper
• The CD8+ T cell repertoire against Her‐2/neu antigens in neu transgenic mice is of low avidity with antitumor activity

  2004cites this paper
• Chapter 70 – Biologic Therapy for Gynecologic Malignancies

  2004cites this paper
• Role of CD4+ T lymphocytes in antitumor immunity.

  2003cites this paper
• Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity

  2003influential citation
• Anti-Her-2/neu-IL-2 or heregulin-IL-2 fusions proteins redirect non-tumor specific CTL to the tumor site for tumor eradication

  2003cites this paper
• A translational bridge to cancer immunotherapy

  2003cites this paper
• A Mutated f 3-Catenin Gene Encodes a Melanoma-spec

  2003cites this paper
• PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

  2003cites this paper
• Immunity to cancer through immune recognition of altered self: studies with melanoma.

  2003cites this paper
• Enhanced Immune Presentation of a Single-chain Major Histocompatibility Complex Class I Molecule Engineered to Optimize Linkage of a C-terminally Extended Peptide*

  2003cites this paper
• Peptide Induction of Surface Expression of Class I MHC

  2003cites this paper
• Oncogenes as Targets for Cancer Vaccines

  2003cites this paper
• [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].

  2003cites this paper
• Homology Between an Alloantigen and a Self MHC Allele Calibrates the Avidity of the Alloreactive T Cell Repertoire Independent of TCR Affinity1

  2003cites this paper
• TCR Affinity Alloreactive T Cell Repertoire Independent of MHC Allele Calibrates the Avidity of the Homology Between an Alloantigen and a Self

  2003cites this paper
• Multicopy Suppressors of ninl-l*

  2003cites this paper